SEATTLE, April 24, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its first quarter financial results on Thursday, May 2, 2013, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update, at 4:30 p.m. ET ( 1:30 p.m. PT). Access to the event can be obtained as follows:
Thursday, May 2 1:30 p.m. PT/ 4:30 p.m. ET/ 10:30 p.m. CET1-877-941-6010 (domestic) +1 480-629-9644 (international)
To access the live audio webcast or the subsequent archived recording, visit CTI's website, www.celltherapeutics.com. Webcast and telephone replays of the conference call will be available at approximately two hours after completion of the call. Callers can access the replay by dialing 1-800-358-3474 (domestic) or +1 303-590-3030 (international). The access code for the replay is #4615670. The telephone replay will be available until Thursday, May 9, 2013.
About Cell Therapeutics, Inc.Cell Therapeutics (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit the company's website at www.CellTherapeutics.com. Media and Investor Contacts: Cell Therapeutics, Inc.
Monique Greer +1 206.272.4343 email@example.com Ed Bell+1 206.272.4345 firstname.lastname@example.org In Europe CTI Life Sciences Limited, Milan Branch Laura VillaElena BellaciccaE: CTI_EUInvestors@CTI-Lifesciences.comT: +39 02 89659700F: +39 02 89659719 http://www.celltherapeutics.com/italiano
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts